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Cytokine therapy can activate potent, sustained antitumor re-
sponses, but collateral toxicity often limits dosages. Although
antibody–cytokine fusions (immunocytokines) have been designed
with the intent to localize cytokine activity, systemic dose-limiting
side effects are not fully ameliorated by attempted tumor targeting.
Using the s.c. B16F10 melanoma model, we found that a nontoxic
dose of IL-2 immunocytokine synergized with tumor-specific anti-
body to significantly enhance therapeutic outcomes compared with
immunocytokine monotherapy, concomitant with increased tumor
saturation and intratumoral cytokine responses. Examination of
cell subset biodistribution showed that the immunocytokine associ-
ated mainly with IL-2R–expressing innate immune cells, with more
bound immunocytokine present in systemic organs than the tumor
microenvironment. More surprisingly, immunocytokine antigen
specificity and Fcγ receptor interactions did not seem necessary
for therapeutic efficacy or biodistribution patterns because immu-
nocytokines with irrelevant specificity and/or inactive mutant Fc
domains behaved similarly to tumor-specific immunocytokine.
IL-2–IL-2R interactions, rather than antibody–antigen targeting, dic-
tated immunocytokine localization; however, the lack of tumor target-
ing did not preclude successful antibody combination therapy.
Mathematical modeling revealed immunocytokine size as another
driver of antigen targeting efficiency. This work presents a safe,
straightforward strategy for augmenting immunocytokine efficacy by
supplementary antibody dosing and explores underappreciated factors
that can subvert efforts to purposefully alter cytokine biodistribution.
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Cytokines constitute a class of small immunomodulatory pro-teins, many of which possess tumoricidal properties useful
for cancer immunotherapy (1, 2). One of the earliest successful
cytokine therapies, IL-2, which has antitumor functions that
include the activation of natural killer (NK) and cytotoxic T cells,
can induce durable remissions in 5–10% of patients with meta-
static melanoma and renal cell carcinoma, malignancies with poor
prognoses (3). However, IL-2’s potent immunostimulatory abili-
ties often cause serious side effects, including life-threatening
vascular leak syndrome, during systemic IL-2 administration. In
theory, cytokine side effects might be mitigated by localizing cyto-
kine activity to tumor tissues. One approach for tumor targeting has
been to link cytokines to antibodies specific for tumor-associated
antigens, generating immunocytokines (1, 2). Treatment with IL-2
immunocytokines has proven to be superior to treatment with
equivalent antibody and cytokine given as separate agents (4–7).
Nonetheless, systemic dose-limiting side effects have been ob-
served after IL-2 immunocytokine administration, despite its ex-
pected tumor localization (8, 9).
Based on previous findings that antibody-dependent cell-
mediated cytotoxicity (ADCC) plays an important role in immu-
nocytokine efficacy (2), we hypothesized that IL-2 immunocytokine
efficacy could be enhanced without introducing toxicity by the
administration of additional tumor-specific antibody. We show
in a syngeneic solid tumor model that IL-2 immunocytokine in-
deed synergized with antitumor antibody to significantly prolong
survival. Although the antibody component has generally been
expected to mediate immunocytokine localization, we show instead
that the IL-2 moiety entirely governed biodistribution, explaining
our unexpected observation that immunocytokines recognizing ir-
relevant antigen performed equivalently to tumor-specific immu-
nocytokines when combined with antibody. Mathematical modeling
complemented our experimental results and highlights molecular
size as another determinant of tumor-targeting outcome.
Results
Generation and Characterization of IL-2 Immunocytokines. Cytokine
fusion to the IgG light-chain rather than the heavy-chain C ter-
minus yields constructs that are more stable and possess greater
effector functions (10, 11). To generate immunocytokines of this
format, we fused murine IL-2 to full-length mouse IgG2a mol-
ecules with variable regions specific for either TRP1 antigen ex-
pressed by murine melanomas or CEA, a human tumor marker,
to produce TA99-IL2 and sm3E-IL2, respectively (Fig. 1A and
Dataset S1). The purified proteins were predominantly homog-
enous monomers (Fig. S1A) and showed the expected masses on
SDS/PAGE (Fig. S1B). As confirmed by flow cytometry, both
immunocytokines retained the ability to bind simultaneously to
cell surface antigens and anti–IL-2 antibody (Fig. S1C). Assess-
ment of simultaneous binding function also revealed excellent
thermal stability and reasonable proteolytic stability for the two
constructs (Fig. S1D). Moreover, the immunocytokines exhibited
similar in vitro specific activity to WT IL-2 as measured by IL-2–
dependent CTLL-2 cell proliferation (Fig. 1B). When injected
into mice, TA99-IL2 and sm3E-IL2 displayed plasma β half-lives
of 11–14 h (Fig. 1C and Table S1), considerably longer than that
of WT IL-2, which is on the order of minutes (12). Both the
Significance
Cytokines (potent immunostimulatory proteins) exert powerful
antitumor effects but often cause severe whole-body in-
flammation when used as cancer therapies. Contrary to the cur-
rent paradigm that fusion to antitumor antibodies can constrain
cytokine activity to tumors, we have found that, for some im-
munocytokines incorporating the cytokine IL-2, the cytokine moi-
ety overrides antibody-mediated targeting, localizing the fusion
protein to IL-2 receptor-expressing cells rather than tumor cells.
Although the IL-2 immunocytokines did not selectively home to
tumors, they persisted longer in circulation than free IL-2, such
that a nontoxic immunocytokine dose could synergize with tumor-
specific antibody to cure mice with aggressive solid tumors.
Author contributions: A.T. and K.D.W. designed research; A.T., B.H.K., C.F.O., and T.N.
performed research; A.T., B.H.K., C.F.O., T.N., and K.D.W. analyzed data; and A.T. and K.D.W.
wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1To whom correspondence should be addressed. Email: wittrup@mit.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1416159112/-/DCSupplemental.
3320–3325 | PNAS | March 17, 2015 | vol. 112 | no. 11 www.pnas.org/cgi/doi/10.1073/pnas.1416159112
immunocytokines’ larger size and the presence of the antibody
Fc region, allowing recycling through the neonatal Fc receptor,
likely account for this extended plasma persistence. Injection of
immunocytokines but not antibody also resulted in splenomegaly,
providing additional evidence of bioactivity (Fig. S1E).
Combination Therapy Using Immunocytokine and Tumor-Specific
Antibody Provides Synergistic Antitumor Responses. We tested the
antitumor efficacy of TA99-IL2 by administering it to C57BL/6
mice bearing established syngeneic B16F10 melanoma tumors,
which express TRP1. To circumvent IL-2 toxicity, we used an im-
munocytokine dosing regimen that did not induce systemic toxicity
as measured by weight loss (Fig. S2A). Despite significantly delaying
tumor growth compared with PBS, TA99-IL2 was insufficient for
prolonged tumor control (Fig. 2A and Fig. S2B). We hypothesized
that the lack of durable remissions could be caused by insufficient
tumor saturation with the immunocytokine, because antitumor
activity has been correlated with a therapeutic antibody’s ability
to penetrate throughout tumor tissue (13). Because antitumor
antibodies such as TA99 are generally far better tolerated than
cytokines and can independently elicit tumoricidal immunity (14),
we combined our original TA99-IL2 dose with additional TA99
murine IgG2a antibody to attain a dosage theoretically predicted
to fully saturate the tumors (15). This combination therapy sig-
nificantly improved the survival of tumor-bearing mice compared
with treatment with TA99-IL2 alone, yielding long-term survivors
(Fig. 2A and Fig. S2B). The additional antibody did not lead to
systemic toxicity (Fig. S2A), although normal melanocytes also
express TRP1. Interestingly, when mice were treated with equi-
molar WT murine IL-2 in lieu of TA99-IL2 concurrently with
TA99, survival was similar to that of PBS-treated controls (Fig.
2A and Fig. S2B), indicating that some attribute of the immu-
nocytokine [e.g., size, antigen specificity, or Fcγ receptor (FcγR)
binding] was required for synergistic efficacy.
To determine if treatment efficacy corresponded with tumor
saturation by therapeutic agents, we generated a B16F10 cell line
that stably expressed EGFP (Fig. S3). We then assessed tumor
saturation by injecting Alexa Fluor 647-conjugated TA99-IL2 and/
or TA99 into mice bearing B16F10-GFP tumors and analyzing
fluorescent protein binding to resected disaggregated tumor cells
by flow cytometry. Although the combination of TA99-IL2 and
TA99 resulted in nearly complete tumor saturation, TA99-IL2
alone labeled <2% of GFP+ tumor cells (Fig. 2B). Strikingly,
a 25.4-μg TA99 dose equimolar to the TA99-IL2 dose yielded
significantly higher saturation (Fig. 2B), although TA99-IL2
bound readily to B16F10 cells in vitro (Fig. S1C). Thus, the
presence of IL-2 in the immunocytokine significantly reduced the
degree of antibody saturation in the tumor. These results indicate
that tumor saturation with antibody is necessary but not suffi-
cient for effective tumor growth control in this model. When we
monitored the intratumoral immune response posttreatment using
a 32-plex cytokine assay, we detected a general increase in cyto-
kine expression after administration of TA99-IL2 + TA99 vs.
IL-2 + TA99 or TA99-IL2 (Fig. 2C). Mice treated with TA99-IL2 +
TA99 exhibited significantly higher expression of MIG and MIP-2
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Fig. 1. Characterization of IL-2 immunocytokines. (A) IL-2 is fused to the light-chain C termini of an anti-TRP1 (TA99) or anti-CEA (sm3E) IgG molecule.
(B) Immunocytokine bioactivity was measured by incubating CTLL-2 cells with varying concentrations of IL-2 species and detecting cell proliferation by WST-1
assay. Symbols indicate individual data points (normalized to control cells treated with 50 ng/mL IL-2); lines indicate fits to a four-parameter logistic curve.
EC50 values were determined to be 0.1883 ng/mL (IL-2), 0.1943 ng/mL (TA99-IL2), and 0.2551 ng/mL (sm3E-IL2) from n = 2 independent experiments performed
in triplicate. (C) Plasma clearance curves of Alexa Fluor 647-labeled immunocytokines (50 μg i.v.). Plasma mean fluorescence intensities (symbols) were
normalized to the initial time point and fit to a biphasic exponential decay curve (lines). Error bars depict SEM (n = 3).
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Fig. 2. Tumor-specific antibody synergizes with IL-2 immunocytokine for
improved antitumor responses. (A) Kaplan–Meier survival curves for mice
inoculated s.c. with 106 B16F10 tumor cells and then treated on days 6, 12,
18, 24, and 30 with i.v. PBS, 6 μg IL-2 + 100 μg TA99, 32 μg TA99-IL2, or 32 μg
TA99-IL2 + 100 μg TA99 (n = 9–13). (B) Mice bearing established s.c. B16F10-
GFP tumors were injected i.v. with Alexa Fluor 647-labeled TA99-IL2 (32 μg)
and/or TA99 (100 μg unless otherwise noted), and tumors were harvested
24 h later for flow cytometry (n = 5). Percentages of Alexa Fluor 647+GFP+
cells are shown (mean percentage ± SEM). (C) Heat map depicts differential
intratumoral cytokine responses in mice bearing established s.c. B16F10
tumors after treatment with IL-2 + TA99, TA99-IL2, or TA99-IL2 + TA99
compared with PBS-treated controls (n = 5–6). Mice were injected with the
doses specified in A, and 24 h later, tumors were resected and homogenized
for analysis using a bead-based multiplex assay. Color bar varies on a loga-
rithmic scale. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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(P < 0.0001 vs. IL-2 + TA99 and TA99-IL2), chemokines known
to recruit antitumor effector cells, including NK cells, T cells, and
neutrophils (16, 17). The chemokine IP-10, a close relative of
MIG, was also significantly up-regulated in mice treated with
TA99-IL2 + TA99 compared with those treated with IL-2 + TA99
(P < 0.05). Overall, elevated intratumoral cytokine responses
corresponded with better prognosis, linking immune activation
with antitumor efficacy.
Synergy Between Tumor-Specific Antibody and Immunocytokines
Requires Neither Immunocytokine Antigen Specificity nor FcγR
Interactions. Fusion of a full-length IgG to a cytokine allows not
only targeting through the antibody variable region, but also ADCC
and complement-dependent cytotoxicity effector functions and
extended half-life through the Fc region. To examine which of
these properties contributes to immunocytokine synergy with TA99,
we compared the effectiveness of various immunocytokines. Sur-
prisingly, treatment with sm3E-IL2, which recognizes an antigen
absent in mice, had an almost identical effect on B16F10 tumor
growth as TA99-IL2 therapy, acting synergistically with TA99 to
promote long-term survival (Fig. 3A and Fig. S2). This unexpected
observation shows that tumor targeting by the antibody variable
region is dispensable for synergy with TA99. A single point mu-
tation (D265A) in the antibody Fc region ablates interactions
with FcγRs and complement, abolishing IgG effector functions
(18). We introduced the D265A mutation to TA99-IL2 and
sm3E-IL2 and found that the D265A immunocytokines did not
perform significantly differently from their parent immunocyto-
kines (Fig. 3A and Fig. S2), suggesting that immunocytokine
Fc-mediated effector functions are also nonessential for effective
combination therapy with TA99. Neither antigen specificity nor
effector function competence affected immunocytokine satura-
tion of established B16F10-GFP tumors, because there were no
significant labeling differences among groups treated with fluo-
rescently labeled immunocytokines (Fig. 3B). This observation
contradicts predictions that tumor-targeted agents should display
greater tumor accumulation than their nontargeted counter-
parts. After coinjection of fluorescently labeled TA99, ∼100%
of GFP+ cells were bound to fluorescent therapeutic agents
(Fig. 3B). Because immunocytokine antigen specificity and Fc
effector functions both were unnecessary for therapeutic syn-
ergy with TA99, IL-2 plasma persistence is likely the key factor
in the combination therapy. Moreover, IL-2 with a short half-
life did not produce durable remissions when coinjected with
TA99 (Fig. 2A).
The IL-2 Moiety Governs Immunocytokine Localization. Our un-
anticipated findings that immunocytokine antigen specificity did
not affect therapeutic efficacy or immunocytokine distribution to
tumor cells (Figs. 2 and 3) prompted us to develop an assay for
tracking immunocytokine and antibody localization at a cellular
level. A similar approach has been successfully used in moni-
toring nanoparticle trafficking (19). We first examined the dis-
tribution of TA99 antibody and found that, as expected, TA99
binding was enriched intratumorally for immune populations
[e.g., dendritic cells (DCs), macrophages, and NK cells] known
to express FcγR (14, 20), which can interact with the antibody
Fc region (Fig. 4). This enrichment presumably stems from tu-
mor localization mediated by antibody recognition of the TRP1
antigen on the surface of tumor cells. In the blood and spleen,
monocytes/macrophages exhibited the greatest percentage of
binding to TA99 (Fig. 4), consistent with the high expression of
FcγR by these cells (20). However, IL-2 fusion drastically altered
the binding distribution pattern of its partner, and for TA99-IL2,
NK and natural killer T (NKT) cells dominated binding. Nearly
all NK cells and a high percentage of NKT cells in the analyzed
organs were bound to TA99-IL2 (Fig. 4). In contrast, a lower
percentage of monocytes/macrophages, particularly in the tumor,
showed binding to TA99-IL2 vs. TA99 (Fig. 4 and Fig. S4A), al-
though no differences in absolute cell numbers were observed
(Fig. S4B). Notably, ∼80% of circulating DCs were TA99-IL2–
bound (Fig. 4). Greater percentages of intratumoral CD8+ T cells
and Tregs bound to the immunocytokine compared with corre-
sponding populations from other organs, which is attributable to
the IL-2 moiety given that both cell types do not express FcγR
and did not bind to naked TA99 (Fig. 4). Remarkably, the
binding distribution of sm3E-IL2 closely mirrored that of TA99-
IL2 (Fig. 4), showing that the antigen specificity of the parent
antibody had negligible effects on immunocytokine localization.
To determine the contribution of Fc–FcγR interactions to im-
munocytokine localization, we monitored the binding distribution
of D265A mutant immunocytokines. In most cases, ablation of
Fc–FcγR interactions did not change the distribution patterns.
However, for all analyzed compartments, a higher percentage of
Tregs bound to the D265A than to the corresponding parent
immunocytokine (Fig. S4A). Intratumoral CD8+ T cells also
showed greater binding to sm3E-IL2 D265A than to sm3E-IL2
(Fig. S4A). Although the parent immunocytokines could con-
ceivably mediate immune cell depletion through their intact
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Fig. 3. IL-2 immunocytokine antigen specificity and Fc receptor interactions
are dispensable for therapeutic synergy with tumor-specific antibody.
(A) Kaplan–Meier survival curves for mice inoculated s.c. with 106 B16F10
tumor cells and then treated on days 6, 12, 18, 24, and 30 with i.v. PBS, 32 μg
sm3E-IL2, 32 μg sm3E-IL2 + 100 μg TA99, 32 μg TA99-IL2 D265A, 32 μg TA99-
IL2 D265A + 100 μg TA99, 32 μg sm3E-IL2 D265A, or 32 μg sm3E-IL2 D265A +
100 μg TA99 (n = 10–13). (B) Mice bearing established s.c. B16F10-GFP tumors
were injected i.v. with therapeutic dosages of Alexa Fluor 647-labeled ver-
sions of the indicated agents, and tumors were harvested 24 h later for flow
cytometry (n = 5). Percentages of Alexa Fluor 647+GFP+ cells are shown
(mean percentage ± SEM). ***P < 0.001; ****P < 0.0001.
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effector activity, there were no significant differences in Treg or
CD8+ T-cell numbers between mice treated with D265A and
parent immunocytokines (Fig. S4B). Overall, the four examined
immunocytokines had only the IL-2 component in common but
displayed distribution patterns strikingly similar to one another
and distinct from TA99 (Fig. 4 and Fig. S4A). In addition, the
immune cell lineages exhibiting the highest percentage binding
to immunocytokines have all been documented to express
IL-2R but not necessarily FcγR at appreciable levels in previous
studies (14, 21) and our own experience (Fig. S5). Ex vivo blood
binding analysis further corroborated the existence of distinct
FcγR- and IL-2R-expressing cell populations that act as sinks for
therapeutic proteins containing intact Fc or IL-2 domains, re-
spectively, in a dose- and affinity-dependent manner (Fig. S4C).
These data strongly suggest that the IL-2–IL-2R interaction was
the main determinant of these immunocytokine distributions, with
Fc–FcγR interactions playing, if anything, a minor role.
Immunocytokines Predominantly Remain Systemic and Associate
with Innate Immune Cells Regardless of Antigen Specificity or FcγR
Interactions. Quantifying the percentages of immunocytokine-
bound (IC+) cells highlights the immune cell lineages showing the
greatest relative binding to immunocytokines but does not allow
comparisons of immunocytokine abundances between different
organs or cell types. For each immune lineage of interest, we
approximated the amounts of immunocytokine associated with
each organ by multiplying the total number of IC+ cells from that
organ by the median fluorescence intensity, which is proportional
to the number of fluorescent molecules binding to the cells. For
all four immunocytokines, the partitioning patterns among organs
were remarkably similar (Fig. 5A). Immunocytokines bound to
the DC, NK cell, and NKT cell populations were mostly found
in the spleen, with a smaller percentage located in the blood.
Meanwhile, more than 80% of immunocytokines bound to CD8+
T cells and Tregs were found in the spleen, with very little in the
blood. In contrast, only a small proportion of immunocytokines
localized in the tumor, and even less was found in the draining
lymph node. Because these immunocytokines nonetheless showed
therapeutic efficacy when combined with TA99 antibody (Figs.
2A and 3A), high tumor uptake is not necessary for effective
antitumor therapy. Ablation of Fc–FcγR interactions did not
appreciably alter organ distribution (Fig. 5A). Although the tu-
mor-specific TA99-IL2 had been expected to accumulate to
a greater extent in tumors than the nontumor-specific sm3E-IL2,
the two immunocytokines actually displayed similar tumor uptake
proportions (Fig. 5A). These results indicate that neither antigen
specificity nor Fc mutations greatly impact immunocytokine dis-
tribution at the organ level and that the majority of immunocy-
tokine associates with systemic rather than tumor-proximal
immune cells. Next, we estimated the fraction of immunocytokine
or antibody bound to each immune cell lineage by summing the
products of IC+ lineage cells and median fluorescence intensity
for the analyzed organs. The largest proportion of all four
immunocytokines was associated with NK cells, with DCs and
NKT cells harboring the second and third largest proportions,
respectively (Fig. 5B). In contrast, NK cells bound a smaller
percentage of TA99 antibody, and monocytes/macrophages and
NKT cells played far greater roles in interacting with TA99 than
with the immunocytokines (Fig. 5B). Once again, the distribution
patterns of TA99-IL2 were distinct from those of TA99 and
closely resembled those of sm3E-IL2, TA99-IL2 D265A, and
sm3E-IL2 D265A, suggesting that for these immunocytokines,
antibody variable and Fc region-mediated interactions were largely
superseded by IL-2–mediated interactions.
Mathematical Modeling Reveals Size Dependence of Immunocytokine
Targeting. To further explore additional parameters for immu-
nocytokine targeting effectiveness and the generalizability of our
observations, we developed a simple ordinary differential equa-
tion (ODE) model (Fig. 6A and Fig. S6). We modeled the two
most common formats for immunocytokines currently in clinical
trials (1, 2): large (full-length IgG) and small (diabody consist-
ing of dimeric single-chain variable fragment). Moreover, we
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considered different rates of tumor antigen endocytosis to
account for antigen targets with varying turnover rates. As
validation, we input pharmacokinetic parameters from several
prior studies of therapeutic protein distribution into our model
and found that the predicted biodistributions closely matched
experimental data (Fig. S7). Unlike experiments using radio-
or fluorescently labeled immunocytokines, this model dis-
tinguishes when immunocytokines are active (extracellular and
capable of signaling through cytokine receptors). To assess the
effects of tumor targeting, we computed expected tumor-to-
blood exposure ratios for large and small immunocytokines.
Consistent with our experimental results, the predicted tumor-
to-blood ratios for active large immunocytokines are poor,
even with a very slow rate of antigen endocytosis (Fig. 6B). No-
tably, large immunocytokines recognizing rapidly endocytosed
antigens have tumor-to-blood ratios <1, localizing to tumors to an
even lesser extent than immunocytokines with irrelevant antigen
specificity, because fast turnover translates to a depletion effect.
In contrast, small immunocytokines have much better predicted
tumor-to-blood exposure ratios at varying endocytosis rates (Fig.
6B). These results indicate that another major determinant of
immunocytokine targeting efficiency is the balance between sys-
temic and tumor clearance. Small immunocytokines have much
faster blood clearance than large ones, minimizing systemic ex-
posure, whereas tumor clearance mostly depends on antigen
turnover rates, which are unaffected by immunocytokine size.
Hence, for the same antigen target, small immunocytokines can
achieve higher tumor-to-blood ratios than large ones. Another
way to view the benefits of immunocytokine tumor targeting is to
determine relative cytokine activities in different compartments
based on the EC50 of IL-2. Although large immunocytokines
maintain constant activities ∼100% in both the blood and tumor,
small immunocytokines can achieve a window in which the cy-
tokine is active in the tumor but not in the blood (Fig. S8). Im-
portantly, in the model, we did not account for immunocytokine
uptake into extratumoral cellular sinks to parse out the effects
of size independent of this process. However, as we have shown
(Figs. 2B and 5), immunocytokine consumption outside the tumor
can dominate overall distribution.
Discussion
Immunocytokines are designed to localize cytokine therapy to
tumors but still suffer from systemic dose-limiting toxicities
(5, 9). We have shown that tumor-specific antibody synergizes
with IL-2 immunocytokines to produce long-term remissions in the
poorly immunogenic B16F10 tumor model. Similarly, cotherapy
with a tumor vasculature-directed IL-2 immunocytokine and an
anti-CD20 antibody significantly enhanced survival in a lymphoma
xenograft model in immunocompromised mice lacking T cells (6);
we report here for the first time, to our knowledge, an immu-
nocytokine/antibody combination strategy for the treatment of
established syngeneic solid tumors in mice with an intact im-
mune system. Surprisingly, it is the IL-2 moiety rather than
immunocytokine antigen specificity that almost completely
determines cellular and organ biodistribution. Neither immuno-
cytokine tumor targeting nor effector functions are required for or
even seem to contribute to effective combination therapy. Using
a mathematical model, we show that, in general, slow systemic
clearance may further impair antigen targeting efficiency by IgG-
based immunocytokines, such as the ones tested here.
This study shows that the only essential contribution of anti-
body fusion to IL-2 efficacy in this model is prolonging IL-2
plasma half-life from minutes to roughly one-half of a day. This
observation is consistent with previous hypotheses that IL-2’s
rapid clearance hampers its therapeutic use (21, 22). In the clinic,
IL-2 therapy requires frequent infusions (3), and in a preclinical
trial using the hu14.18-IL2 immunocytokine, which has a half-life
of 3–4 h, complete eradication of murine neuroblastoma required
combination with continuous IL-2 administration (23). Saturation
of tumor cells by ADCC-activating molecules and a robust intra-
tumoral cytokine response likely account for the impressive anti-
tumor activity exhibited by the immunocytokine/TA99 antibody
combination therapies (Figs. 2 and 3). Additional work is nec-
essary to definitively identify key immune cell types and mecha-
nisms underlying the synergistic tumor control observed for IL-2
immunocytokines and TA99.
Numerous reports have characterized immunocytokine bio-
distribution at the organ level (1), but to our knowledge, this is
the first to examine the cellular-level distribution of multispecific
proteins, allowing us to identify unexpected trends in localization
patterns. Although naked TA99 was driven by antigen recogni-
tion to accumulate intratumorally, fusion to IL-2 introduced
a competing IL-2–IL-2R interaction that overrode both antigen
specificity and FcγR interactions as the key mechanism for lo-
calization (Figs. 4 and 5). In retrospect, IL-2R binding probably
explains the significantly reduced association of TA99-IL2 with
tumor cells compared with that of equimolar TA99 (Fig. 2B).
Similar instances of cytokine–cytokine receptor-dominated bio-
distribution for tumor vasculature-targeted IFN-γ immunocyto-
kines have been observed (24, 25). Moreover, the markedly faster
plasma clearance of immunocytokines relative to their parent
antibodies as reported by several groups (26, 27) may reflect
extensive binding of immunocytokines to IL-2R–expressing cells.
Circulating immune cells expressing CD122, which may correspond
to the immunocytokine-bound NK cells that we detected, have
been linked to IL-2 toxicity (28) but may also contribute to ther-
apeutic efficacy. Overall, the relationship between immunocytokine
binding and efficacy or toxicity requires additional investigation.
It may seem paradoxical that NK and NKT cells, which express
the intermediate-affinity IL-2R, bind a greater proportion of
immunocytokine than Tregs and activated CD8+ T cells, which
express the high-affinity IL-2R. However, NK and NKT cells are
generally more abundant than Tregs and activated CD8+ T cells,
especially in the blood (29), the first point of contact for i.v.-
administered immunocytokines. On entering the blood, immu-
nocytokines first encounter and bind to NK and NKT cells,
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which may preclude efficient distribution to other sites that
contain Tregs and activated CD8+ T cells. Analogously, although
the affinities of TA99 for TRP1 and IL-2 for intermediate-
affinity IL-2R are both ∼10−9 M (21, 30), i.v.-injected immuno-
cytokines encounter and associate with circulating IL-2R–
expressing immune cells well before they can reach TRP1+ tumor
cells, resulting in predominant immunocytokine accumulation in
systemic rather than tumor-proximal compartments.
Our results suggest that in targeted therapy development, the
biodistribution of any construct with multiple potential targeting
interactions should be directly assessed rather than assumed. If
the desired antigen targeting is not achieved, several general
strategies may be used to promote selective localization, with the
caveat that such targeting may not be required for therapeutic
efficacy, which was the case for this study. For accessible solid
tumors, intratumoral administration may exhibit superior anti-
tumor activity and reduced systemic toxicity compared with the
i.v. route (31–33), consistent with our findings that i.v.-injected
immunocytokine resided predominantly in the blood and spleen
rather than the tumor (Fig. 5A). Antigen choice also impacts
targeting efficacy: in contrast to our results, several studies have
shown that immunocytokines specific for antigens expressed by
tumor vasculature or liquid/disseminated tumors perform better
than irrelevant immunocytokines (4, 7, 34), likely because these
antigens are in closer contact with the blood and thus, more
accessible than solid tumor antigens. Alternatively, the affinity of
the cytokine for its receptor can be weakened, so that cytokine
function is potentially restored only on high-avidity binding to
tumor cells (35). Finally, our mathematical model suggests that
small-format immunocytokines may intrinsically exhibit better
antigen-targeting specificity than large-format immunocytokines
because of size-dependent transport properties (rapid systemic
clearance and diffusion by smaller molecules).
In conclusion, we have explored a facile strategy for improving
immunocytokine antitumor efficacy and uncovered limitations for
selective targeting by multicomponent constructs. Addition of
tumor-specific antibody to existing immunocytokine therapies may
be a promising option for enhancing clinical outcomes without
introducing incremental toxicity. Because extended plasma per-
sistence seems to be far more important than tumor localization
for effective IL-2 synergy with naked antibody, simply prolonging
IL-2 circulation by fusion to serum albumin or antibody Fc region
may allow equivalent efficacy when combined with tumor-specific
antibody. This nontargeted, persistent cytokine could be readily
coadministered with clinically approved antibodies, circumventing
the need to develop a new immunocytokine for each tumor anti-
gen. Future studies will be needed to validate these experimental
and theoretical concepts in additional tumor models using a variety
of cytokine moieties, antigen targets, and immunocytokine formats.
Materials and Methods
Detailed methods are provided in SI Materials and Methods. In summary,
IL-2 immunocytokines were generated by PCR-based cloning, produced by
transient HEK293-F cell transfection, purified using protein A beads, and
characterized in vitro and in vivo. TA99 antibody was produced by a stable
HEK293-F cell line and purified using protein A beads. Fluorescently labeled
proteins were generated by reaction with Alexa Fluor 647 NHS ester. C57BL/6
mice were inoculated s.c. with 106 B16F10 or B16F10-GFP tumor cells, and
tumors were allowed to establish before treatment with i.v. IL-2, immunocy-
tokine, and/or TA99 for tumor control assessment, intratumoral cytokine
measurement, or flow cytometry analysis. Mathematical modeling was per-
formed using MATLAB.
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